secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0000914475-24-000210
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Q3 INGREZZA sales $613M (+26% YoY); raises FY2024 guidance; $300M buyback
--------------------------------------------------------------------------------

- INGREZZA net product sales $613M in Q3 2024, up 26% YoY; raised 2024 sales guidance to $2.30-$2.32B.
- Total revenues $622.1M (+25% YoY); GAAP EPS $1.24 vs $0.82; Non-GAAP EPS $1.81 vs $1.54.
- Board authorized $300M share repurchase plan; intends to enter accelerated share repurchase.
- New CEO Kyle W. Gano appointed effective Oct 11, 2024; Phase 2 data for NBI-1117568 triggered $35M milestone.
- Terminated licenses for luvadaxistat (CIAS) and NBI-827104; terminations expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447524000210/0000914475-24-000210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447524000210/nbix-20241030.htm
  HTML page:      https://secwatch.observer/filing/0000914475-24-000210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer